NSCLC
New combo lung cancer therapy improves survival over single-line treatment
AURORA, Colo. (Dec. 14, 2010) — A combination therapy for treating cancer discovered at the University of Colorado Cancer Center showed improved survival rates in patients with advanced non-small cell lung cancer (NSCLC), according to results from…
VCU Massey discovery could lead to breakthrough for non-small cell lung cancer
Richmond, Va. (Dec. 3, 2010) — Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-sma…
Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
MILAN, ITALY – October 10, 2010 – Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared …
Vaccine technique shows potential against common form of lung cancer
In a demonstration of vaccine therapy’s potential for treating lung cancer, scientists report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated. Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases.